BridgeBio (BBIO) Q3 2026 earnings review
BridgeBio heart drug sales rise, while three FDA decisions near
BridgeBio, a developer of medicines for genetic diseases, grew sales of its heart drug Attruby while hiring staff for three upcoming drug launches. U.S. Attruby revenue rose 14% from last quarter to $253 million, and chief executive Neil Kumar highlighted two real-world studies showing fewer hospital stays than Pfizer's rival medicine. A one-off $75 million milestone payment from European partner Bayer shrank the reported operating loss to $12 million, though by our math the underlying loss was $87 million.
| U.S. Attruby product sales | $253.2M +14% from last quarter |
|---|---|
| Total revenue | $353.2M includes $75M one-off Bayer payment |
| Operating loss, excluding Bayer payment | $86.6M $107.1M loss last quarter (by our math) |
| Launch timeline outlook | Unchanged 3 FDA decision dates set within 7 months |
⚖️ Verdict: 🟢 Bullish
The story got better because regulators set firm Priority Review decision dates for all three pipeline drugs within the next seven months, and a $934 million preferred stock raise lifted cash to $1.5 billion to pay for their rollouts. One caution: quarterly growth for Attruby slowed from 23% in the second quarter by our math, while unpaid customer bills jumped to $375 million and kept cash burn elevated.
The question now is whether Attruby can grow fast enough to cover the cost of three new sales teams before those drugs start bringing in cash. If real-world hospital data wins over doctors, operating losses will keep shrinking; if growth slows further, launch costs will widen the loss again. Next quarter's operating loss without one-off milestone payments will tell.
🐂 Bull Case
Attruby Keeps Gaining First-Line Patients
Attruby, BridgeBio's pill for a fatal heart disease caused by protein buildup called ATTR-CM, continues to win new patients. Chief commercial officer Matt Outten said real-world data reinforces its place as "the stabilizer of choice" against Pfizer's rival drug, tafamidis. U.S. sales reached $253.2 million, up 13.9% from the second quarter by our math.
- U.S. Attruby sales: $253.2 million, up $145.2 million from a year ago
- Hospitalization risk: 25% lower than tafamidis in an analysis of 2,684 patients
- Clinical worsening: 34% lower risk than tafamidis in a peer-reviewed claims study
These independent health-record studies matter because doctors still prescribe Pfizer's older drug to most newly diagnosed patients. Showing fewer hospital stays in everyday practice gives doctors a reason to start patients on Attruby first, though quarterly growth slowed from 23.2% in the prior quarter by our math.
What to watch: fourth-quarter U.S. Attruby revenue and new heart data at the American Heart Association meeting in November. A bigger dollar gain than this quarter's $31 million would show the hospital data is winning over doctors faster.
Three Drug Decisions Arrive Within Seven Months
The biotechnology group is moving from a single-product company to a multi-drug seller. U.S. regulators granted Priority Review to three experimental rare-disease medicines, setting decision dates between November 2026 and May 2027. "Our field teams for all three programs are hired and ready to serve these communities from day one," Outten said.
- BBP-418 for limb-girdle muscular dystrophy (muscle-wasting disease): FDA decision on November 27, 2026
- Oral infigratinib for achondroplasia (the most common form of dwarfism): FDA decision on February 4, 2027
- Encaleret for ADH1 (low blood calcium disorder): FDA decision on May 8, 2027
Having sales reps in the field before approval speeds up early prescriptions once regulators clear a drug. For BBP-418, reps have already visited over 70% of the specialized muscular dystrophy clinics that treat 70% of U.S. patients, and plan to reach 90% by the November decision date.
What to watch: the FDA approval decision for BBP-418 on November 27, 2026. Approval gives BridgeBio a second commercial drug and a rare pediatric voucher it can sell for cash.
Preferred Stock Raise Funds Launches and Buybacks
Launching three rare-disease drugs at once requires heavy upfront spending. BridgeBio solved its funding need by issuing $933.9 million in Series A preferred stock, lifting cash and marketable securities to $1.54 billion, which it said is "fully funding all three launches and expansion indications." The company also spent $252.5 million over nine months to buy back common shares, using half of its $500 million buyback plan.
What to watch: preferred stock dividend payments and net cash used in operating activities in the fourth quarter. Shrinking cash burn would show Attruby sales can pay the new preferred dividends without dipping into the cash reserve.
🐻 Bear Case
A One-Off Milestone Masked the Operating Loss
BridgeBio highlighted that its operating loss shrank to $11.6 million, making the business look close to breaking even. That figure relies on a one-time $75.0 million payment from partner Bayer after European and Japanese sales of acoramidis (sold there as BEYONTTRA) hit a target. Without that payment, the operating loss was $86.6 million by our math.
- Selling and overhead costs: $200.9 million (56.9% of revenue, down 57.1 percentage points from a year ago)
- Research and development costs: $143.5 million (40.6% of revenue, down 52.9 percentage points)
- Preferred stock dividends and accretion: $26.3 million, widening the net loss for common shareholders to $83.0 million
Hiring three new sales forces pushed selling and overhead costs up by $63.2 million from a year ago. While the underlying loss improved from $107.1 million in the second quarter by our math, recurring drug sales still do not cover the expanding cost base.
What to watch: fourth-quarter operating loss excluding any milestone payments. A loss above $87 million would show that launch hiring is outrunning Attruby's quarterly revenue gains.
Unpaid Customer Bills Jump Faster Than Sales
Growing revenue only funds operations when customers pay their bills on time. Accounts receivable, the money owed by distributors and partners for drugs already delivered, climbed to $375.1 million from $139.4 million at the end of 2025. That $235.6 million tie-up of working capital accounted for most of the $312.6 million cash burn over the first nine months.
Part of the third-quarter balance likely reflects the $75.0 million Bayer milestone earned during the period, which was not yet collected. Even stripping out that milestone, unpaid bills reached $300.1 million by our math, exceeding the quarter's $253.3 million in product sales.
What to watch: accounts receivable on the year-end balance sheet. A balance still growing faster than product revenue after Bayer pays its milestone would signal slower collections from U.S. specialty pharmacies.
Confirmed Patient Counts Trail Claims Estimates
Rare-disease launches depend on finding patients before approval. For encaleret in ADH1, a genetic calcium disorder, BridgeBio previously spotted nearly 2,000 patients in insurance claims, yet has confirmed just over 600 through genetic testing, up from about 500 last quarter. For BBP-418, it has identified over 500 U.S. patients, while delaying its European application to the first half of 2028 to wait for 36-month trial data.
What to watch: the number of genetically confirmed ADH1 and LGMD2I/R9 patients reported next quarter. Adding only 100 confirmed ADH1 patients a quarter would cap the initial prescription wave when encaleret launches in May 2027.
Risks this quarter didn't answer
Three standing commercial and competitive concerns received no update in the third-quarter earnings release.
- Rival clinical trial: BridgeBio gave no update on how a competing ATTR-CM trial (CARDIO-TTRansform) will affect doctors' first-line prescribing.
- Generic competition timing: the release added nothing on the expected 2031–2032 entry of generic tafamidis in the U.S.
- Diagnostic scan supplies: management did not mention whether earlier shortages of PYP heart scans are still slowing new patient diagnoses.
👓 Other Themes
New Antibody Program Targets Amyloid Removal
Attruby works by stabilizing proteins so they stop forming new toxic clumps in the heart, and chief executive Neil Kumar said he is "heartened by how consistently the evidence for acoramidis keeps pointing in the same direction." To clear deposits that are already there, BridgeBio named a new antibody drug candidate, BBP-717, and plans to file for FDA permission to start human trials in 2027.
💲 Other KPIs
Royalty income nearly quintupled from $4.3 million a year ago and rose from $15.4 million in the second quarter by our math. BridgeBio earns these payments on partner Bayer's sales of BEYONTTRA in Europe and Japan, which flows straight to profit after small license fees.
Stockpiled drug supplies more than doubled from $26.8 million at year-end 2025, rising 81% since the first quarter by our math. The drugmaker is building inventory to supply expanding Attruby demand and prepare for three upcoming commercial launches, which tied up $35.6 million in cash over nine months.
Share count rose 2.2% from 191.9 million a year ago and increased slightly from 194.8 million in the first quarter. Employee stock-option exercises and share awards added more shares than the company retired through its $252.5 million stock buyback.
🔮 Guidance
Unchanged. The FDA set an exact decision date of November 27, 2026 under Priority Review, keeping the U.S. launch on track for late 2026. No advisory committee meeting is planned.
New. BridgeBio plans to file for European approval in the first half of 2028 after positive talks with national regulators. The filing will wait for final 36-month data from the FORTIFY trial, expected in late 2027 or early 2028.
Unchanged. The regulator accepted the application with Priority Review and set a February 4, 2027 target date, matching the company's earlier plan for an early-to-mid 2027 launch. European regulators are also reviewing the drug for a potential approval in the second half of 2027.
Unchanged. The FDA granted Priority Review with a May 8, 2027 decision date and no advisory panel planned, while European approval could follow in the second half of 2027. Separately, topline Phase 3 results for a second, larger indication in chronic hypoparathyroidism are expected in early 2028.
❓ Key Questions
What are the dividend and conversion terms on preferred stock?
BridgeBio raised $933.9 million in Series A preferred stock and recorded $26.3 million in third-quarter dividends and value adjustments. The release does not state the annual dividend rate or how many common shares the preferred stock can convert into.
Why did unpaid bills grow faster than product sales?
Accounts receivable climbed $169.9 million since the first quarter to $375.1 million. Even if the $75.0 million Bayer milestone sits in that figure, unpaid bills rose by nearly $95 million while quarterly product revenue grew by $72.8 million.
What is Attruby's exact share of new prescriptions?
Management said Attruby's share of newly diagnosed patients rose again, after passing 25% earlier in the year. Naming the current percentage would show how fast the new real-world hospital studies are closing the gap with Pfizer.
Why will European regulators wait for 36-month BBP-418 data?
The FDA accepted 12-month data for Priority Review, but BridgeBio will not file in Europe until the first half of 2028. That delays access to more than 4,000 European patients, a larger group than in the U.S.